Greenwich LifeSciences interview scheduled for RedChip programme on Bloomberg TV and CNBC
Greenwich LifeSciences CEO Snehal Patel is scheduled to discuss GLSI-100, clinical development and manufacturing progress during a RedChip television interview airing on Bloomberg TV and CNBC.
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel is scheduled to appear on RedChip Companies’ sponsored Small Stocks, Big Money™ programme, with broadcasts planned on Bloomberg TV and CNBC. The interview will cover the company’s GLSI-100 immunotherapy, the Phase III FLAMINGO-01 trial, clinical expansion and manufacturing activities.
The interview is scheduled for Bloomberg TV on Saturday, November 14, at 7:00 p.m. Eastern Time (ET). CNBC is scheduled to air the programme on Sunday, November 15, at 11:30 a.m. ET.
RedChip states that Bloomberg TV is available in an estimated 73 million homes across the United States, while CNBC is available in approximately 90 million U.S. households.
Greenwich LifeSciences is developing GLSI-100 as an immunotherapy intended to help prevent the return of HER2-positive breast cancer after surgery and standard antibody treatment. The treatment combines the GP2 peptide with GM-CSF to stimulate an immune response against recurring cancer cells.
The company said a Phase IIb clinical trial showed an approximately 80% reduction in breast cancer recurrence. It said the result supports the treatment’s potential to address an unmet medical need and reduce the risk of metastatic disease.
Patel is expected to discuss early results from the ongoing Phase III FLAMINGO-01 trial. Greenwich LifeSciences reported strong immune responses and preliminary recurrence trends among patients regardless of HLA type.
The open-label, non-HLA-A02 cohort has shown an approximately 80% reduction in recurrence based on the company’s preliminary observations. Greenwich said the finding is consistent with the earlier Phase IIb result, while also stating that the observations remain early and require further validation.
According to the company, broader eligibility beyond the initially targeted HLA-A02 group could potentially increase its annual target population from approximately 44,000 to 88,000 patients across the United States and Europe. This is an estimate from Greenwich LifeSciences and is subject to the development of the programme.
Greenwich LifeSciences said it has approximately 160 clinical sites across the United States and Europe. The company is continuing patient enrolment and pursuing protocol modifications intended to expand eligibility and strengthen its planned interim analyses.
The company also said a potential expansion to approximately 200 trial sites is under consideration, with additional clinical data presentations and interim analyses anticipated. These activities remain part of the ongoing clinical development programme.
On manufacturing, Greenwich LifeSciences said the FDA is reviewing manufacturing data and that commercially manufactured GLSI-100 clinical supplies are being used in the U.S. Phase III trial.
Greenwich LifeSciences describes itself as a clinical-stage biopharmaceutical company focused on GP2-based immunotherapy for preventing breast cancer recurrence in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein. The company states that HER2 is expressed in 75% of breast cancers at low, intermediate and high levels.
RedChip Companies provides investor relations and media services to Greenwich LifeSciences and receives compensation for those services. RedChip also states that it does not independently verify all information contained in the announcement and makes no representation or warranty regarding its accuracy or completeness.
Greenwich LifeSciences CEO Snehal Patel is scheduled to appear on RedChip’s sponsored programme.
The interview is scheduled for Bloomberg TV on Saturday, November 14, at 7:00 p.m. ET and CNBC on Sunday, November 15, at 11:30 a.m. ET.
Greenwich reported an approximately 80% reduction in recurrence in its Phase IIb trial and in preliminary observations from its open-label, non-HLA-A02 cohort.
The company said its Phase III FLAMINGO-01 findings are early and require further validation.
Greenwich reported approximately 160 clinical sites, FDA review of manufacturing data and the use of commercially manufactured GLSI-100 supplies in the U.S. Phase III trial.
Greenwich LifeSciences announced that its CEO, Snehal Patel, will appear in an interview on RedChip Small Stocks, Big Money™, a sponsored television programme. The interview will cover the development of GLSI-100, clinical progress, trial expansion and preparations for potential commercialisation.
The Greenwich LifeSciences interview is scheduled to air on Bloomberg TV on Saturday, November 14, at 7:00 p.m. Eastern Time (ET), and on CNBC on Sunday, November 15, at 11:30 a.m. ET.
Greenwich LifeSciences is developing GLSI-100, an immunotherapy designed to prevent the recurrence of HER2-positive breast cancer following surgery and standard antibody treatment. GLSI-100 combines the GP2 peptide with GM-CSF to stimulate the immune system to recognise and eliminate recurring cancer cells.
Greenwich LifeSciences said GLSI-100 demonstrated an approximately 80% reduction in breast cancer recurrence in a Phase IIb clinical trial. The company said this supported the potential of the treatment to address an unmet medical need and reduce the risk of metastatic disease.
Greenwich LifeSciences said the ongoing Phase III FLAMINGO-01 trial has produced strong immune responses and preliminary recurrence trends in patients regardless of HLA type. The company said these findings are still early and require further validation.
Greenwich LifeSciences said its open-label, non-HLA-A02 patient cohort has shown an approximately 80% reduction in recurrence based on the company’s preliminary observations. The company said the result was consistent with the earlier Phase IIb study, while noting that the findings remain early and require further validation.
Greenwich LifeSciences estimates that broader eligibility could potentially double its annual target population from approximately 44,000 to 88,000 patients across the United States and Europe. The company links this possibility to expanding eligibility beyond the initially targeted HLA-A02 group.
Greenwich LifeSciences said it has approximately 160 clinical sites across the United States and Europe. The company is continuing to advance patient enrolment while pursuing protocol modifications designed to expand eligibility and strengthen its planned interim analyses.
Greenwich LifeSciences said additional clinical data presentations are anticipated, alongside a potential expansion to approximately 200 trial sites and interim analyses ahead. The company also said it is exploring opportunities to expand GLSI-100’s potential applications.
Greenwich LifeSciences said the FDA is reviewing manufacturing data and that commercially manufactured GLSI-100 clinical supplies are being used in the U.S. Phase III trial. The company described this as part of its progress towards commercial-scale manufacturing.
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on developing GP2 to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, which the company says is expressed in 75% of breast cancers at low, intermediate and high levels.
Greenwich LifeSciences trades on NASDAQ under the ticker symbol GLSI, written in the source as NASDAQ:GLSI.
Greenwich LifeSciences is a client of RedChip Companies, which provides investor relations and media services to the company and receives compensation for those services. RedChip also states that it does not independently verify all information in the release and makes no representation or warranty as to its accuracy or completeness.